Adaptive announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response. Continue reading
Adaptive selected today four recipients to receive its Young Investigator Award for February. Winners will receive a $5,000 grant to use towards the purchase of immunoSEQ assays as part of their research in a variety of fields, such as immunology. Continue reading
Scientists at Adaptive have published a paper in the upcoming edition of the Journal of Immunological Methods that demonstrates a new method for determining the relative proportions of CD4+ and CD8+ T cells. Continue reading
Adaptive announced today that Robert Hershberg, M.D., Ph.D., has joined the company’s board of directors. Dr. Hershberg will work closely with the board and management team to focus on corporate strategy and clinical development. Continue reading
Adaptive today introduced clonoSEQ, a clinical assay to measure minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today’s most common pathology tests. clonoSEQ will be available for widespread clinical use by mid-2013. Continue reading
Immune profiling informs clinical decision-making in various hematologic settings Seattle, WA, December 3, 2012 – Adaptive Biotechnologies, a leading provider of next-generation sequencing assays for the adaptive immune system, will be presenting data at the Annual Meeting of the American … Continue reading
SEATTLE, WA, November 12, 2012 – Adaptive Biotechnologies Corporation, a leading provider of next-generation sequencing assays for the adaptive immune system, selected today five recipients to receive its Young Investigator Award for November. Winners will receive a $5,000 grant to … Continue reading
Adaptive Biotechnologies Corporation has named respected industry-veteran Ilan “Lanny” Kirsch, M.D. as its new Senior Vice President of Translational Medicine, responsible for leading the development and launch of clinical diagnostic applications stemming from its immunoSEQ and quanTILfy technology platforms. Continue reading
SEATTLE, WA, September 6, 2012 – Adaptive Biotechnologies Corporation, a leading provider of next-generation sequencing assays for the adaptive immune system, announced today that President and CEO Chad Robins was recently recognized with the Puget Sound Business Journal “40 Under … Continue reading
SEATTLE, WA, September 5, 2012 – A recent study published in The Journal of Immunology details significant discoveries in the understanding of B-cell development that could eventually lead to vaccines to treat HIV more effectively. The research was conducted by … Continue reading
To understand better the technology and science behind immunoSEQ.
